128 related articles for article (PubMed ID: 18180157)
1. Rational design of the first small-molecule antagonists of NHERF1/EBP50 PDZ domains.
Mayasundari A; Ferreira AM; He L; Mahindroo N; Bashford D; Fujii N
Bioorg Med Chem Lett; 2008 Feb; 18(3):942-5. PubMed ID: 18180157
[TBL] [Abstract][Full Text] [Related]
2. Indole-2-amide based biochemical antagonist of Dishevelled PDZ domain interaction down-regulates Dishevelled-driven Tcf transcriptional activity.
Mahindroo N; Punchihewa C; Bail AM; Fujii N
Bioorg Med Chem Lett; 2008 Feb; 18(3):946-9. PubMed ID: 18180158
[TBL] [Abstract][Full Text] [Related]
3. Design of a selective chemical probe for class I PDZ domains.
Fujii N; Shelat A; Hall RA; Guy RK
Bioorg Med Chem Lett; 2007 Jan; 17(2):546-8. PubMed ID: 17074480
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of the NHERF1 PDZ2 domain in complex with the chemokine receptor CXCR2 reveals probable modes of PDZ2 dimerization.
Holcomb J; Jiang Y; Guan X; Trescott L; Lu G; Hou Y; Wang S; Brunzelle J; Sirinupong N; Li C; Yang Z
Biochem Biophys Res Commun; 2014 May; 448(2):169-74. PubMed ID: 24768637
[TBL] [Abstract][Full Text] [Related]
5. An allosteric intramolecular PDZ-PDZ interaction modulates PTP-BL PDZ2 binding specificity.
van den Berk LC; Landi E; Walma T; Vuister GW; Dente L; Hendriks WJ
Biochemistry; 2007 Nov; 46(47):13629-37. PubMed ID: 17979300
[TBL] [Abstract][Full Text] [Related]
6. Development of 3-substituted-1H-indole derivatives as NR2B/NMDA receptor antagonists.
Gitto R; De Luca L; Ferro S; Citraro R; De Sarro G; Costa L; Ciranna L; Chimirri A
Bioorg Med Chem; 2009 Feb; 17(4):1640-7. PubMed ID: 19157884
[TBL] [Abstract][Full Text] [Related]
7. Different conformational dynamics of PDZ1 and PDZ2 in full-length EBP50 analyzed by hydrogen/deuterium exchange mass spectrometry.
Park JY; Duc NM; Kim DK; Lee SY; Li S; Seo MD; Woods VL; Chung KY
Biochem Cell Biol; 2015 Aug; 93(4):290-7. PubMed ID: 25789870
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
Raboisson P; Desjarlais RL; Reed R; Lattanze J; Chaikin M; Manthey CL; Tomczuk BE; Marugán JJ
Eur J Med Chem; 2007 Mar; 42(3):334-43. PubMed ID: 17184884
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of bidentate ligands designed to interact with PDZ domains.
Boucherle B; Vogrig A; Deokar H; Bouzidi N; Ripoche I; Thomas I; Marin P; Ducki S
Bioorg Med Chem; 2011 Jul; 19(14):4346-54. PubMed ID: 21680189
[TBL] [Abstract][Full Text] [Related]
10. Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: from signaling regulation to clinical relevance.
Vaquero J; Nguyen Ho-Bouldoires TH; Clapéron A; Fouassier L
Oncogene; 2017 Jun; 36(22):3067-3079. PubMed ID: 28068322
[TBL] [Abstract][Full Text] [Related]
11. Canonical and Noncanonical Sites Determine NPT2A Binding Selectivity to NHERF1 PDZ1.
Mamonova T; Zhang Q; Khajeh JA; Bu Z; Bisello A; Friedman PA
PLoS One; 2015; 10(6):e0129554. PubMed ID: 26070212
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and screening of support-bound combinatorial peptide libraries with free C-termini: determination of the sequence specificity of PDZ domains.
Joo SH; Pei D
Biochemistry; 2008 Mar; 47(9):3061-72. PubMed ID: 18232644
[TBL] [Abstract][Full Text] [Related]
13. Crystallographic analysis of NHERF1-PLCβ3 interaction provides structural basis for CXCR2 signaling in pancreatic cancer.
Jiang Y; Wang S; Holcomb J; Trescott L; Guan X; Hou Y; Brunzelle J; Sirinupong N; Li C; Yang Z
Biochem Biophys Res Commun; 2014 Apr; 446(2):638-43. PubMed ID: 24642259
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach.
Ueda S; Kato M; Inuki S; Ohno H; Evans B; Wang ZX; Peiper SC; Izumi K; Kodama E; Matsuoka M; Nagasawa H; Oishi S; Fujii N
Bioorg Med Chem Lett; 2008 Jul; 18(14):4124-9. PubMed ID: 18539453
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for NHERF1 PDZ domain binding.
Mamonova T; Kurnikova M; Friedman PA
Biochemistry; 2012 Apr; 51(14):3110-20. PubMed ID: 22429102
[TBL] [Abstract][Full Text] [Related]
16. The role of the NHERF family of PDZ scaffolding proteins in the regulation of salt and water transport.
Seidler U; Singh AK; Cinar A; Chen M; Hillesheim J; Hogema B; Riederer B
Ann N Y Acad Sci; 2009 May; 1165():249-60. PubMed ID: 19538313
[TBL] [Abstract][Full Text] [Related]
17. First X-ray cocrystal structure of a bacterial FabH condensing enzyme and a small molecule inhibitor achieved using rational design and homology modeling.
Daines RA; Pendrak I; Sham K; Van Aller GS; Konstantinidis AK; Lonsdale JT; Janson CA; Qiu X; Brandt M; Khandekar SS; Silverman C; Head MS
J Med Chem; 2003 Jan; 46(1):5-8. PubMed ID: 12502353
[TBL] [Abstract][Full Text] [Related]
18. Rational design of a nonpeptide general chemical scaffold for reversible inhibition of PDZ domain interactions.
Fujii N; Haresco JJ; Novak KA; Gage RM; Pedemonte N; Stokoe D; Kuntz ID; Guy RK
Bioorg Med Chem Lett; 2007 Jan; 17(2):549-52. PubMed ID: 17055267
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel indole series of EP1 receptor antagonists by scaffold hopping.
Hall A; Billinton A; Brown SH; Chowdhury A; Giblin GM; Goldsmith P; Hurst DN; Naylor A; Patel S; Scoccitti T; Theobald PJ
Bioorg Med Chem Lett; 2008 Apr; 18(8):2684-90. PubMed ID: 18378447
[TBL] [Abstract][Full Text] [Related]
20. Identification of prostaglandin D2 receptor antagonists based on a tetrahydropyridoindole scaffold.
Beaulieu C; Guay D; Wang Z; Leblanc Y; Roy P; Dufresne C; Zamboni R; Berthelette C; Day S; Tsou N; Denis D; Greig G; Mathieu MC; O'Neill G
Bioorg Med Chem Lett; 2008 Apr; 18(8):2696-700. PubMed ID: 18359630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
